Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $69.21 which represents a slight increase of $1.22 or 1.79% from the prior close of $67.99. The stock opened at $68.14 and ...

In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total ...

Exact Sciences Corp (NASDAQ:EXAS) EVP of Precision Oncology, Brian Baranick, has recently sold a portion of his company stock, according to the latest filings. On September 18, Baranick sold 929 ...

Exact Sciences (EXAS) stock rises as company announces release of data for blood-based cancer test on August 16. Read more ...

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its second quarter 2024 investor ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mark ...

Citi has reaffirmed its Buy rating and $80.00 stock price target. Exact Sciences has also disclosed promising initial data on its blood-based colorectal cancer (CRC) test. The test showed an ...

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...

The initial results suggest that Exact’s test could be an alternative to others on the market, but the findings come from a ...

Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $64.12 which represents a slight increase of $5.74 or 9.83% from the prior close of $58.38. The stock opened at $58.46 and ...

Exact Sciences Corp (NASDAQ:EXAS) EVP of Precision Oncology, Brian Baranick, has recently sold a portion of his company stock, according to the latest filings. On September 18, Baranick sold 929 ...

BTIG and Piper Sandler have raised their price targets to $82 and $85 respectively, both maintaining a positive rating on Exact Sciences shares. Citi has reaffirmed its Buy rating and $80.00 stock ...